
This electron microscope image provided by the National Institutes of Health shows humanvirions, colorized blue, and anti-RSV F protein/gold antibodies, colorized yellow, shedding from the surface of human lung cells. The U.S. approved the first vaccine for RSV on Wednesday, May 3, 2023 shots to protect older adults against a respiratory virus that's most notorious for attacking babies but endangers their grandparents, too.
The Food and Drug Administration decision makes GSK's shot, called Arexvy, the first of several potential vaccines in the pipeline for RSV to be licensed anywhere.
The move sets the stage for adults 60 and older to get vaccinated this fall — but first, the Centers for Disease Control and Prevention must decide if every senior really needs RSV protection or only those considered at high risk from the respiratory syncytial virus. CDC's advisers will debate that question in June.
Comment: It seems like the 'speed of science' is back with a vengeance: The US is stocking vaccines for a hypothetical smallpox bio-attack